synagis - palivizumab injection, solution
(Palivizumab)Swedish Orphan Biovitrum Ab (Publ)
Usage: Synagis prevents serious lower respiratory tract disease caused by RSV in pediatric patients: premature infants (≤35 weeks gestation, ≤6 months old), or children ≤24 months with bronchopulmonary dysplasia requiring treatment, or hemodynamically significant congenital heart disease. Not indicated for RSV treatment.